A Phase 1 Study to Evaluate the Pharmacokinetics of a Tablet Formulation of ABBV-722 and the Effect of Food on Its Bioavailability in Healthy Adult Subjects
Latest Information Update: 27 Feb 2026
At a glance
- Drugs ABBV 722 (Primary)
- Indications Idiopathic pulmonary fibrosis; Systemic scleroderma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 24 Feb 2026 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Feb 2026 New trial record